Lipid Nanoparticle and Adeno-Associated Virus Platform

Nucleic acid therapeutics hold great promise for treating diseases. Lipid nanoparticles (LNPs) represent the most advanced platform for RNA delivery and RNA-based therapeutics. Adeno-associated viruses (AAVs) are the most effective gene delivery vehicles to drive long-term transgene expression in gene therapy. Profit from these advanced technologies and our experience by collaborating with us!


We offer a comprehensive suite of analytical tools and assays for the characterization and evaluation of novel LNPs and AAVs. Our platform is designed to assist you in gaining valuable insights into the in vitro delivery mechanisms, in vivo biodistribution patterns, tissue targeting efficacy, and immune response dynamics of these cutting-edge delivery systems.

One of the key services we offer is bioluminescence in vivo imaging, which enables the noninvasive monitoring and quantification of RNA delivery by utilizing luciferase as a reporter gene. This powerful technique allows for real-time visualization and assessment of the distribution and persistence of delivered RNA within living organisms.

To further investigate tissue targeting, we employ hEPO (erythropoietin) ELISA, a method that enables the detection and quantification of targeted delivery to specific tissues or organs. By measuring the levels of hEPO in these tissues, we can assess the efficiency and selectivity of the delivery system in reaching its intended destination.

Moreover, our capabilities include the detection and visualization of viral- and LNP-delivered oligonucleotides using RNA in situ hybridization RNAscope™ and barcode sequencing.

We support the tolerability assessment of your asset by ex vivo inflammatory cytokine profiling, liver enzyme profiling (AST, ALT, ALP, GLDH, GGT), and complement activation assessment.

RNA in situ hybridization (RNAscope™) for in situ biodistribution of viral and LNP-delivered oligonucleotides.